New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Aligos Therapeutics, Inc. (ALGS) vs VistaGen Therapeutics, Inc. (VTGN)

Aligos Therapeutics, Inc. and VistaGen Therapeutics, Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and VistaGen Therapeutics, Inc. are of similar size ($8.8M and $8.6M). Aligos Therapeutics, Inc. grew revenue faster over the last twelve months: 1,171.6% against 230.2%. Aligos Therapeutics, Inc. has the higher net margin (−197.0% vs −2,475.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Aligos Therapeutics, Inc. leads on 9 and VistaGen Therapeutics, Inc. on 6.

Valuation

Metric ALGS VTGN Biotechnology median
P/E n/m n/m 8.49
P/S 0.39 2.99 8.56
P/B 1.15 0.47 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.26 0.21 0.69
EV/Sales (0.56) (5.43) 8.00
Earnings yield (512.10%) (851.06%) (35.81%)
Free cash flow yield (529.27%) (853.69%) (25.41%)

Profitability

Metric ALGS VTGN Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (215.55%) (2,543.22%) 0.00%
Net margin (197.01%) (2,475.56%) 0.00%
Free cash flow margin (204.07%) (2,549.39%) 0.00%
Return on equity (159.46%) (144.95%) (51.58%)
Return on assets (84.46%) (112.97%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALGS VTGN Biotechnology median
Revenue growth (TTM) 1,171.58% 230.24% 7.20%
EPS growth (last fiscal year) 88.30% (9.58%) 29.04%
Revenue growth, 5-year CAGR — 3.10% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALGS VTGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.77 2.64 4.79
Net debt to EBITDA 0.87 0.63 1.01

Dividend

Metric ALGS VTGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALGS VTGN Biotechnology median
Market cap 8.81m 8.62m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack